Fig. 2

FDA-approved therapeutic drugs for lung cancers. a Distribution of therapeutic drugs for lung cancers during the past 31 years (adapted from [126]). b Microtubule inhibitor. c EGFR inhibitors and EGFR-directed mAb. d EGFR- and MET-bispecific antibody and EGFR inhibitor for NSCLC with EGFR^ex20ins mutations. e ALK inhibitors. f MET inhibitors. g RET inhibitors. h Multitarget TKI. i KRAS^G12C-targeted small-molecule inhibitor. j DNA topoisomerase inhibitor and DNA alkylating agent for SCLC